Biocon Biologics UK PLC
Biocon Biologics Limited is a global biosimilars company with capabilities across discovery, CMC, large-scale biologics manufacturing, clinical development, analytical characterization, regulatory submissions and pharmacovigilance. The company operates multi-site manufacturing, conducts randomized clinical and PK/PD studies (including euglycaemic clamp studies for insulins), publishes peer-reviewed research, and has obtained marketing authorizations and market entries in multiple jurisdictions including the European Union, United States, Canada and Japan.
Industries
Nr. of Employees
Very Large (1000+)
Biocon Biologics UK PLC
Products
Global biosimilars portfolio (insulins, monoclonal antibodies, recombinant proteins)
A portfolio of biosimilar therapeutics developed and commercialized for global markets, covering insulin products, monoclonal antibodies and recombinant protein therapeutics.
Global biosimilars portfolio (insulins, monoclonal antibodies, recombinant proteins)
A portfolio of biosimilar therapeutics developed and commercialized for global markets, covering insulin products, monoclonal antibodies and recombinant protein therapeutics.
Expertise Areas
- Biosimilars development
- CMC and bioprocess scale-up
- Analytical development and bioanalytical quantification
- Clinical trial management and bioequivalence/PK‑PD studies
Key Technologies
- Yeast expression systems (Pichia pastoris)
- Mammalian cell culture for monoclonal antibodies
- Upstream and downstream bioprocess development
- Analytical assay development and stability testing